X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
hematology (27) 27
index medicus (27) 27
humans (23) 23
oncology (17) 17
aged (16) 16
female (15) 15
multiple myeloma (15) 15
male (14) 14
middle aged (14) 14
adult (12) 12
aged, 80 and over (12) 12
bortezomib (10) 10
patient outcomes (8) 8
survival (8) 8
dexamethasone (7) 7
multiple-myeloma (7) 7
antineoplastic combined chemotherapy protocols - therapeutic use (6) 6
cancer (6) 6
care and treatment (6) 6
hematology, oncology and palliative medicine (6) 6
multiple myeloma - drug therapy (6) 6
prognosis (6) 6
treatment outcome (6) 6
biomarkers (5) 5
cyclophosphamide (5) 5
lenalidomide (5) 5
light-chain amyloidosis (5) 5
multiple myeloma - pathology (5) 5
bortezomib - administration & dosage (4) 4
disease-free survival (4) 4
drug therapy (4) 4
expression (4) 4
follow-up studies (4) 4
multiple myeloma - genetics (4) 4
multiple myeloma - mortality (4) 4
patients (4) 4
survival analysis (4) 4
survival rate (4) 4
thalidomide (4) 4
thalidomide - analogs & derivatives (4) 4
abridged index medicus (3) 3
antineoplastic combined chemotherapy protocols - administration & dosage (3) 3
biomarkers - blood (3) 3
biopsy (3) 3
bone marrow - pathology (3) 3
chemotherapy (3) 3
chromosome aberrations (3) 3
cytogenetics (3) 3
dexamethasone - administration & dosage (3) 3
endothelial dysfunction (3) 3
glomerular filtration rate (3) 3
health aspects (3) 3
lymphoid neoplasia (3) 3
macroglobulinemia (3) 3
melphalan (3) 3
mortality (3) 3
multiple myeloma - diagnosis (3) 3
multiple myeloma - therapy (3) 3
pomalidomide (3) 3
proportional hazards models (3) 3
refractory multiple-myeloma (3) 3
risk (3) 3
safety (3) 3
stem-cell transplantation (3) 3
therapy (3) 3
abnormalities (2) 2
al amyloidosis (2) 2
amyloidosis (2) 2
analysis (2) 2
article (2) 2
bisphosphonate-related osteonecrosis (2) 2
bisphosphonates (2) 2
bortezomib - adverse effects (2) 2
cells (2) 2
cohort studies (2) 2
competing risk (2) 2
cooperative-oncology-group (2) 2
correspondence (2) 2
creatinine (2) 2
development and progression (2) 2
diagnosis (2) 2
diphosphonates - adverse effects (2) 2
disease (2) 2
disease progression (2) 2
events (2) 2
genetic aspects (2) 2
hemodialysis (2) 2
ibrutinib (2) 2
immunoglobulin light chains - blood (2) 2
immunoglobulin light-chain amyloidosis - therapy (2) 2
immunomodulatory drugs (2) 2
in situ hybridization, fluorescence (2) 2
in-situ hybridization (2) 2
inflammation (2) 2
kidney diseases - diagnosis (2) 2
kidney diseases - etiology (2) 2
kidney function tests (2) 2
low-dose dexamethasone (2) 2
mechanisms (2) 2
medical colleges (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


American Journal of Hematology, ISSN 0361-8609, 05/2016, Volume 91, Issue 5, pp. 499 - 502
Journal Article
American Journal of Hematology, ISSN 0361-8609, 04/2019, Volume 94, Issue 4, pp. 400 - 407
Journal Article
Journal Article
European Journal of Cancer Care, ISSN 0961-5423, 11/2017, Volume 26, Issue 6, pp. e12787 - n/a
Journal Article
American Journal of Hematology, ISSN 0361-8609, 09/2013, Volume 88, Issue 9, pp. 765 - 770
Journal Article
Journal Article
Journal Article
Blood Cancer Journal, ISSN 2044-5385, 05/2018, Volume 8, Issue 5, pp. 42 - 10
Multiple myeloma (MM) is characterized by bone destruction due to increased bone resorption and decreased bone formation. Semaphorin 4D (CD100, Sema4D) is... 
SYSTEM | CELLS | ONCOLOGY | PLEXINS | CLINICAL-FEATURES | RECEPTORS | HEMATOLOGY | EXPRESSION | Vitamin D | Multiple myeloma
Journal Article
British Journal of Haematology, ISSN 0007-1048, 01/2016, Volume 172, Issue 1, pp. 44 - 47
Journal Article